Pfizer’s Abrocitinib Quick Off The Mark In Atopic Dermatitis

Top-Line Results From Third Phase III Study

 
• By John Davis
Starting_Blocks
• Source: Shutterstock

More from Dermatological

More from Therapeutic Category